Intellia Therapeutics, Inc. (NTLA) fell 43.79% to $14.39, down $11.21, after providing an update on its Magnitude Phase 1/2 clinical trials evaluating NTLA-3001 for alpha-1 antitrypsin deficiency or AATD. The company reported that while early-stage data demonstrated successful in vivo gene editing, efficacy signals were lower than expected, prompting a strategic reassessment of the program's next phase.
Intellia said it remains committed to advancing its CRISPR-based therapeutic pipeline but will "prioritize programs with stronger clinical validation and commercial potential." The company plans to provide further updates on development timelines and cost reductions in upcoming quarters.
On Friday, NTLA opened at $23.80, hit a high of $24.15 and a low of $13.91, compared to a previous close of $25.60 on the NasdaqGS. Trading volume soared well above average. The stock's 52-week range is $13.91 - $37.66.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.